The Efficacy and Safety of IBI351, Cetuximab β Combined With FOLFIRI as First-line /IBI351, Cetuximab β as Second-line in the Treatment of KRAS G12C-mutated Metastatic Colorectal Cancer
PHASE2
This is an open-label, multicenter, single-arm Phase II clinical study, div...
Status
Enrolling By Invitation
Location
The Second Affiliated Hospital, School of Medicine, Zhejiang University
A Multicenter, Single-arm Phase II Study to Evaluate the Efficacy and Safety of Fulzerasib (IBI351) in Combination With Ivonescimab (AK-112) in First-line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer Patients With KRAS G12C Mutation
PHASE2
A multicenter, single-arm Phase II study to evaluate the efficacy and safet...